Sheba Medical Center

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

• Sheba medical center

  Ramat Gan, Israel 52621

  213 trials

• Sheba medical center

  Tel HaShomer, 5265601

  30 trials

• Sheba Medical Center, Tel Hashomer

  Ramat Gan, 52621

  11 trials

• Sheba Medical Center - PPDS

  Ramat Gan, 52621

  8 trials

• Sheba Medical Centre

  Ramat Gan, 5265601

  5 trials

• Sheba Medical Center

  Tel Aviv

  4 trials

• Sheba Medical Center (Site 0070)

  Ramat Gan, 5265601

  3 trials

  • NCT06780098Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

    Contact: Study Coordinator

  • NCT06780085A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

  • NCT06731907A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0601)

  Ramat Gan, 5265601

  3 trials

  • NCT07519772A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

    Contact: Study Coordinator

  • NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    Contact: Study Coordinator

  • NCT05587712Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0801)

  Ramat Gan, 5265601

  3 trials

  • NCT06925750A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

  • NCT06664801A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  • NCT03924856Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

• Sheba Medical Center (Site 0200)

  Ramat Gan, 5265601

  2 trials

  • NCT06894771A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

  • NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

    Contact: Study Coordinator

• Sheba Medical Center (Site 0220)

  Ramat Gan, 5262000

  2 trials

  • NCT03829319Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  • NCT03829332Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

• Sheba Medical Center (Site 1401)

  Ramat Gan, 5265601

  2 trials

  • NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    Contact: Study Coordinator

  • NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

• Sheba Medical Center (Site 1602)

  Ramat Gan, 5265601

  2 trials

  • NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    Contact: Study Coordinator

  • NCT03036488Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

• Sheba Medical Center (Site 1708)

  Ramat Gan, 5265601

  2 trials

  • NCT06008756Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

  • NCT05952856A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

• Sheba Medical Center (Site 2001)

  Ramat Gan, 5265601

  2 trials

  • NCT06459180A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

  • NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

• Sheba Medical Center - Tel Ashomer

  Ramat Gan, Israel 5266202

  2 trials

  • NCT06474104Collection of Blood and Skin Samples From Patients With Primary Mitochondrial Diseases and Healthy Volunteers

    Contact: Yair Anikster, MD

  • NCT04548843A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion

• Ella Institute - Sheba Medical Center

  Ramat Gan, 5265601

  1 trial

  • NCT02908672A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

• Endometriosis Center, Sheba Medical Center

  Ramat Gan, Central District

  1 trial

  • NCT07328061Virtual Reality for Anxiety and Pain Management in Transvaginal Ultrasound for Endometriosis

• Joseph Sagol Neuroscience center, Sheba Medical Center

  Ramat Gan, 5265601

  1 trial

  • NCT06072963COMMETS- Combination MCI Metabolic Syndrome

    Contact: Iscka Yore, BS.c.

• Jusidman Cancer Center, Sheba Medical Center

  Ramat Gan, 5262000

  1 trial

  • NCT07131163Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection

    Contact: Jair Bar, MD-PhD

• Movement Disorders Institute, Sheba Medical Center

  Ramat Gan

  1 trial

  • NCT06602193Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

• Sheba Medical Center - Cancer Center (Site 0002)

  Ramat Gan, 52621

  1 trial

  • NCT03179436Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

• Sheba Medical Center; Center Israel

  Ramat Gan, 5265601

  1 trial

  • NCT05563220Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

• Sheba Medical Center /ID# 145965

  Ramat Gan, 5262100

  1 trial

  • NCT02629159A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

• Sheba Medical Center /ID# 202532

  Ramat Gan, 5239424

  1 trial

  • NCT03104400A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

• Sheba Medical Center /ID# 207468

  Ramat Gan, Tel Aviv 5239424

  1 trial

  • NCT03671148A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

• Sheba Medical Center /ID# 207474

  Ramat Gan, Tel Aviv 5239424

  1 trial

  • NCT03675308A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

• Sheba Medical Center /ID# 244905

  Ramat Gan, Tel Aviv 52621

  1 trial

  • NCT05081557A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

• Sheba Medical Center /ID# 254545

  Ramat Gan, Tel Aviv 52621

  1 trial

  • NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

• Sheba Medical Center - Oncology Division (Site 1501)

  Ramat Gan, 52621

  1 trial

  • NCT04626479Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

• Sheba Medical Center - Oncology Division (Site 3501)

  Ramat Gan, 52621

  1 trial

  • NCT04626518Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

• Sheba Medical Center - Rheumatology

  Ramat Gan, 52621

  1 trial

  • NCT05523167A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

• Sheba Medical Center - Sheba Fund for Health Services and Research

  Ramat Gan, 52621

  1 trial

  • NCT04419649A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

    Contact: Drorit Merkel (principal investigator)

• Sheba Medical Center (Site 0001)

  Ramat Gan, 5265601

  1 trial

  • NCT06045507Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

• Sheba Medical Center (Site 0010)

  Ramat Gan, 5265601

  1 trial

  • NCT06686394Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0180)

  Ramat Gan, 5265601

  1 trial

  • NCT07286149A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0300)

  Ramat Gan, 5265601

  1 trial

  • NCT05853367Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

• Sheba Medical Center (Site 0361)

  Ramat Gan, 5265601

  1 trial

  • NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

    Contact: Study Coordinator

• Sheba Medical center (Site 0387)

  Ramat Gan, 5265601

  1 trial

  • NCT03221426Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

• Sheba Medical Center (Site 0401)

  Ramat Gan, 5265601

  1 trial

  • NCT06863272A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0428)

  Ramat Gan, 5265601

  1 trial

  • NCT06456346Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

• Sheba Medical Center (Site 0460)

  Ramat Gan, 5265601

  1 trial

  • NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0551)

  Ramat Gan, 5265601

  1 trial

  • NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

• Sheba Medical Center (Site 0603)

  Ramat Gan, 5265601

  1 trial

  • NCT06890884A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0677)

  Ramat Gan, 5265601

  1 trial

  • NCT06136650A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0702)

  Ramat Gan, 5265601

  1 trial

  • NCT07634471A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0802)

  Ramat Gan, 5265601

  1 trial

  • NCT07709000A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0803)

  Ramat Gan, 5262100

  1 trial

  • NCT04776148Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

• Sheba Medical Center (Site 0827)

  Ramat Gan, 5265601

  1 trial

  • NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    Contact: Study Coordinator

• Sheba Medical Center (Site 0844)

  Ramat Gan, 5265601

  1 trial

  • NCT03924895Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

• Sheba Medical Center (Site 0902)

  Ramat Gan, 5265601

  1 trial

  • NCT07570173A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

    Contact: Study Coordinator

• Sheba Medical Center (Site 1000)

  Ramat Gan, 5265601

  1 trial

  • NCT06353386Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

• Sheba Medical Center (Site 1100)

  Ramat Gan, 5265601

  1 trial

  • NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

• Sheba Medical Center (Site 1200)

  Ramat Gan, 5265601

  1 trial

  • NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    Contact: Study Coordinator

• Sheba Medical Center (Site 1254)

  Ramat Gan, 5265601

  1 trial

  • NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    Contact: Study Coordinator

• Sheba Medical Center (Site 1300)

  Ramat Gan, 5265601

  1 trial

  • NCT05877547A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

• Sheba Medical Center (Site 1301)

  Ramat Gan, 5265601

  1 trial

  • NCT06422143Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    Contact: Study Coordinator

• Sheba Medical Center (Site 1400)

  Ramat Gan, 5265601

  1 trial

  • NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    Contact: Study Coordinator

• Sheba Medical Center (Site 1407)

  Ramat Gan, 5265601

  1 trial

  • NCT05116189Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

• Sheba Medical Center (Site 1421)

  Ramat Gan, 5265601

  1 trial

  • NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

    Contact: Study Coordinator

• Sheba Medical Center (Site 1450)

  Ramat Gan, 5265601

  1 trial

  • NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    Contact: Study Coordinator

• Sheba Medical Center (Site 1601)

  Ramat Gan, 5265601

  1 trial

  • NCT07489495A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

    Contact: Study Coordinator

• Sheba Medical Center (Site 1675)

  Ramat Gan, 5265601

  1 trial

  • NCT06395103Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    Contact: Study Coordinator

• Sheba Medical Center (Site 1700)

  Ramat Gan, 5265601

  1 trial

  • NCT07190248A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

    Contact: Study Coordinator

• Sheba Medical Center (Site 1701)

  Ramat Gan, 5265601

  1 trial

  • NCT07218029A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

• Sheba Medical Center (Site 1733)

  Ramat Gan, 5265601

  1 trial

  • NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

• Sheba Medical Center (Site 2101)

  Ramat Gan, 5265601

  1 trial

  • NCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

• Sheba Medical Center (Site 2200)

  Ramat Gan, 5265601

  1 trial

  • NCT06312137A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    Contact: Study Coordinator

• Sheba Medical Center (Site 2504)

  Ramat Gan, 5265601

  1 trial

  • NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

• Sheba Medical Center (Site 3000)

  Ramat Gan, 5265601

  1 trial

  • NCT06961006A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

• Sheba Medical Center (Site 3201)

  Ramat Gan, 5265601

  1 trial

  • NCT06780137A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

    Contact: Study Coordinator

• Sheba Medical Center (Site 3302)

  Ramat Gan, 5265601

  1 trial

  • NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    Contact: Study Coordinator

• Sheba Medical Center (Site 3675)

  Ramat Gan, 5265601

  1 trial

  • NCT06941272A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

    Contact: Study Coordinator

• Sheba Medical Center (Site 3701)

  Ramat Gan, 5265601

  1 trial

  • NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    Contact: Study Coordinator

• Sheba Medical Center (Site 4401)

  Ramat Gan, 5265601

  1 trial

  • NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    Contact: Study Coordinator

• Sheba Medical Center (Site 4605)

  Ramat Gan, 5265601

  1 trial

  • NCT05270668Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

• Sheba Medical Center (Site 4675)

  Ramat Gan, 5265601

  1 trial

  • NCT07630974A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

    Contact: Study Coordinator

• Sheba Medical Center (Site 5501)

  Ramat Gan, 5265601

  1 trial

  • NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

    Contact: Study Coordinator

• Sheba Medical Center (Site 707)

  Ramat Gan, 6265601

  1 trial

  • NCT07440225A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

    Contact: Study Coordinator

• Sheba Medical Center, Tel-HaShomer, Tel-Aviv University

  Ramat Gan, 5265601

  1 trial

  • NCT07919015Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

    Contact: Liran Levy, MD